Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00

Pharming Group (NASDAQ:PHAR - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $10.00, but opened at $9.79. Pharming Group shares last traded at $9.59, with a volume of 617 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Price Performance

The company has a market capitalization of $646.94 million, a price-to-earnings ratio of -68.85 and a beta of 0.20. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62. The company has a 50 day simple moving average of $10.70 and a 200 day simple moving average of $11.36.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.08). The firm had revenue of $81.20 million for the quarter, compared to analyst estimates of $71.83 million. Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. As a group, research analysts predict that Pharming Group will post -0.02 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC bought a new stake in Pharming Group (NASDAQ:PHAR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,715 shares of the company's stock, valued at approximately $134,000. Institutional investors own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.